---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-118097"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-12-04T23:59:59+00:00"
generated_at: "2026-05-16T14:53:17.677990+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort

## Summary
- DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).
- High-dose cohort achieved 100% complete response (CR) rate at Month 1 in evaluable patients.
- Phase II expansion will evaluate EB103 in relapsed/refractory B-cell NHL at RP2D.
- Majority of Phase I patients were high-risk, including one with CNS lymphoma.

## SEC filing metadata
- accession: 0001213900-25-118097
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025118097/0001213900-25-118097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025118097/ea0268496-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-118097
- JSON: https://secwatch.observer/filing/0001213900-25-118097.json
- Plain text: https://secwatch.observer/filing/0001213900-25-118097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.